Martin Bischof, brings 25 years of experience in the health care environment. During his career he was holding senior positions in reputable companies like in the originator business of GlaxoSmithKline or in the consumer business of Novartis. Currently heading the finance function in Sandoz, a world leading health care company, for Western Europe and also in the past for Middle East and Africa, his international experience gives him a broad perspective, how businesses and related finance functions have evolved over time and will develop in the future. Leadership and talent development are topics close to his heart.
Business models and related finance service delivery concepts, including technology development, are changing fast and he is of the opinion that finance leadership, business partnering and value creation need to become a top priority for all finance executives. In his view there is a shortage of excellent finance people living and breathing the concept of value creation. As a consequence the finance community need to step-up skill development beyond class room training more seriously, to position the finance function as business partners in a unique way.

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1,000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.